Glaukos At Glaukos we are focused on pioneering new treatments for chronic eye diseases. Innovation is at the core of everything we do.

Our mission at Glaukos is to truly transform vision by pioneering novel platforms that can meaningfully advance the standard of care and improve outcomes for patients suffering from sight-threatening chronic eye diseases. Our mantra “We’ll Go First” embodies our commitment and determination to take chances and push the limits of science and technology to disrupt and improve the legacy treatment paradigms in glaucoma, corneal disorders and retinal diseases. ​

​Please note when clicking links in our content you will be led outside of the Glaukos page. The site you opt to connect to does not adhere to our privacy policy. You are solely responsible for your interactions on outside websites. ​

Important Safety Information​
https://www.glaukos.com/important-safety-information/

​COMMUNITY GUIDELINES: ​
Glaukos welcomes interactions and will respond to questions, comments and feedback, but responses may be delayed or limited. ​

Posts and comments contain the opinions and views of other users and Glaukos is not responsible for their accuracy or reliability. ​

​Do not post about financial, legal and regulatory issues, unsubstantiated claims about products, profanity, defamatory, offensive, discriminatory or demeaning content, threats, violence, illegal behavior, health or medical advice, false or misleading information, personal health information, or proprietary, confidential or sensitive information. ​

Follow Facebook's posting guidelines and terms of use. ​

By participating, you promise to comply with these guidelines, but we reserve the right to remove any posts that do not comply. Continuous violations may result in removal from the follower list and inability to receive news, comment or message/contact us. ​

Disclaimers: ​
Accounts followed by or following Glaukos social media channels do not indicate endorsement of the account, their products and services or content they publish. ​

Glaukos may provide links or references to other sites as part of its content, but it does not take responsibility for the content from those sites and shall not be liable for damages or injuries arising from it. These links are provided as a convenience only. ​

Glaukos reserves all rights to the channels, including the right to add, remove or modify content, discontinue the account, accept/reject followers and respond to comments. ​

Only Glaukos and its authorized users may represent Glaukos. Any other representation of Glaukos without authorization will result in legal action. ​

​Medical Side Effects/Adverse Events: ​
If you believe you have experienced any medical side effects or reactions from the Glaukos iLink cross-linking procedure or iStent portfolio of products, consult your physician or healthcare professional and report it to Glaukos by calling 1-844-528-3376, Option 1 or by contacting the FDA at 1-800-FDA-1088. ​

​Avoid sharing personal health information on social media channels, but if you do share information about any side effects, Glaukos may contact you for more information. Posts about side effects may be removed from our channels due to legal requirements. ​

Glaukos will not store or use your personal information, but if you report any adverse events or product issues, we need to store and use identifying information about you to submit it to Glaukos and/or regulatory authorities. ​

​Please be aware that Facebook also has access to information shared on our channels, refer to Facebook's Privacy Policy for more details. ​

Epioxa Is Here – Discover What’s Possible You’re invited to join us for a breakfast discussion on Epioxa—the first and o...
03/09/2026

Epioxa Is Here – Discover What’s Possible

You’re invited to join us for a breakfast discussion on Epioxa—the first and only FDA-approved, non-invasive, epithelium-on oxygen-enriched corneal cross-linking therapy, featuring panel members Larissa Gouvea, MD, Maanasa Indaram, MD, and Susan DeGroot, MBA.

This symposium includes information on how Epioxa is changing the standard of care for patients as well as a review of the clinical data.

📍Westin Seaport, Marina Ballroom | Boston, MA
🗓 Saturday, March 21, 2026
⏰ 6:45 AM – 7:45 AM

Register today to be part of what’s next. Visit: https://fs12.formsite.com/glaukos/loyddskuu3/index

Visit epioxa.com/important-safety-information for Important Safety Information.

Today we celebrate Employee Appreciation Day, and we couldn’t be more grateful for the incredible people who bring our m...
03/06/2026

Today we celebrate Employee Appreciation Day, and we couldn’t be more grateful for the incredible people who bring our mission to life every day.

Our employees are the driving force behind our innovation, our progress, and our vision for the future. Thank you for your dedication, expertise, and unwavering commitment to excellence.

We’re proud of the work we do — and even prouder of the exceptional team behind it. Thank you for all that you do.

Glaukos has achieved an unprecedented milestone as we have now supplied over 3 million interventional glaucoma implants ...
03/04/2026

Glaukos has achieved an unprecedented milestone as we have now supplied over 3 million interventional glaucoma implants globally!

We continue to advance the standard of care through interventional treatment options to help improve the lives of glaucoma patients around the world.

Make a BIG impact in Interventional Glaucoma. Glaukos is proud to sponsor the ASOA Business of Interventional Glaucoma p...
03/02/2026

Make a BIG impact in Interventional Glaucoma.

Glaukos is proud to sponsor the ASOA Business of Interventional Glaucoma program—designed to empower and educate your practice on IG integration.

This one-of-a-kind event delivers the tools and strategies needed to successfully implement IG into your practice, including opportunities to:
• Interact with leading IG experts
• Gain real-world strategies for IG adoption and management
• Network with like-minded peers
• Join sessions tailored for every department in your practice

📍 The Westin DC Downtown | Washington, DC
🗓 Thursday, April 9, 2026
⏰ 8:00 AM – 3:00 PM

Register today and be part of what’s next. Visit: https://www.asoa.org/education-and-meetings/business-of-interventional-glaucoma
Use code: BIGS10

Glaukos is dedicated to improving the lives of people with eye diseases around the world and we are committed to investi...
02/27/2026

Glaukos is dedicated to improving the lives of people with eye diseases around the world and we are committed to investing in solutions and programs to drive awareness for those living with rare diseases.

The future of glaucoma care is evolving — and we invite you to be part of the conversation. Join us for an exclusive mor...
02/04/2026

The future of glaucoma care is evolving — and we invite you to be part of the conversation. Join us for an exclusive morning session on Addressing Myths and Redefining Glaucoma Care with iDose TR and iStent infinite. Learn from experts, connect with peers, and explore what’s next in glaucoma innovation.

📅 Thursday, February 19
🕢 7:15am–8:15am PST
📍 Omni Rancho Las Palmas Resort
🥐 Breakfast will be provided

Register for the breakfast here: https://fs12.formsite.com/glaukos/35gbhqvd4r/index

We look forward to seeing you there!

May cause increases in intraocular pressure, iritis, and dry eye.
Visit https://bit.ly/iDoseTR_PI for full Prescribing Information.
Visit https://bit.ly/iDoseISI for Important Safety Information.
Visit https://bit.ly/iStentInfinite_ISI for Important Safety Information.

We are grateful to be named a 2025 Most Honored Company by Extel (formerly Institutional Investor)—with additional recog...
02/02/2026

We are grateful to be named a 2025 Most Honored Company by Extel (formerly Institutional Investor)—with additional recognition for Best CEO, Best CFO, Best Company Board, and Best IR in the Health Care Technology sector.

Based on independent feedback from thousands of global investment professionals, this recognition reflects our team’s dedication to strong leadership, transparency, and long-term value creation.

This achievement belongs to every Glaukos employee. Thank you for the commitment, collaboration, and purpose-driven work that continues to set us apart. 👏

Approximately 12 million Americans are living with glaucoma today. Because the disease often has no symptoms in its earl...
01/28/2026

Approximately 12 million Americans are living with glaucoma today. Because the disease often has no symptoms in its early stages, many may not realize they are affected. It progresses slowly, often without symptoms, and can lead to permanent vision loss.

At Glaukos, we’re committed to transforming the standard of care for chronic eye diseases like glaucoma. This January, during Glaucoma Awareness Month, we encourage patients and providers alike to prioritize proactive, informed eye health conversations.

Reference: Market Scope. 2024 Glaucoma Pharmaceutical Report.

  is committed to investing in the future of ophthalmology. We've achieved many firsts in clinical studies over the past...
12/22/2025

is committed to investing in the future of ophthalmology. We've achieved many firsts in clinical studies over the past several years. With each innovation, we are transforming standards of care and improving patient lives.​

Contact us to learn more about our unrivaled pipeline of novel therapies: www.glaukos.com/contact-us/

12/18/2025

At , we're committed to advancing ophthalmic treatment worldwide. While pursuing our goals, we've developed a world-class organization. Our performance
has been recognized by an array of voices across the industry. ​

Learn more about how we lead at Glaukos.com

11/20/2025

The Charitable Foundation is dedicated to helping others—in our own community and beyond. Throughout 2025, our product donations have provided underserved patients with meaningful, safe, and long-term ophthalmic care.​

Learn more about our philanthropic efforts at https://bit.ly/3tCs0So

Interventional glaucoma (IG) is reshaping the treatment landscape for patients. Discover how with the Interventional Gla...
11/14/2025

Interventional glaucoma (IG) is reshaping the treatment landscape for patients. Discover how with the Interventional Glaucoma Project. Featuring expert-led webinars and peer-reviewed articles, the Interventional Glaucoma Project is your go-to content source for everything IG. ​

Learn more: https://bit.ly/47i7oyt

Address

1 Glaukos Way
Aliso Viejo, CA
92656

Alerts

Be the first to know and let us send you an email when Glaukos posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Glaukos:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

At Glaukos we are focused on pioneering new treatments for chronic eye diseases.

Glaucoma: Learn more about your treatment options: https://www.glaukos.com/glaucoma/

Keratoconus: Learn more about your treatment options: https://www.glaukos.com/corneal-health/

Retinal Diseases: Learn more: https://www.glaukos.com/retinal-diseases